IBA and Framatome form Ekalia for At-211 production

[Marlin]

IBA and Framatome form Ekalia for At-211 production

https://www.ans.org/news/2026-10-19/article-8498/iba-and-framatome-form-ekalia-for-at211-production/

[Core Content]

Framatome and Ion Beam Applications have established a joint venture named Ekalia to develop industrial-scale production facilities for astatine-211. The newly formed company plans to invest 30 million euros in a production site in Nantes, France, with construction expected to begin in 2027. A second pilot facility is also planned in the United States to support the medical isotope supply chain for targeted cancer therapies.

On Friday, Framatome and Ion Beam Applications announced the next step in their plan to advance the industrial-scale production of astatine-211 in Europe and the United States. The partners have formed a jointly owned company, Ekalia, through which they will deploy a network of At-211 production sites close to customers.

According to IBA, the first production site is planned in Nantes, France, and Ekalia expects to invest €30 million (about $33.6 million) in it. The permit application has been submitted, the start of construction is anticipated in early 2027, and the site is expected to become operational in 2028. A second pilot site is planned in the United States, though the location and timing have yet to be confirmed.

Read the full article at ans.org:
https://www.ans.org/news/2026-10-19/article-8498/iba-and-framatome-form-ekalia-for-at211-production/